First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults.

[1]  M. Lievens,et al.  A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge. , 2021, Vaccine.

[2]  A. Dicko,et al.  Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. , 2021, The New England journal of medicine.

[3]  O. Traoré,et al.  Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial , 2021, The Lancet.

[4]  S. Chaudhury,et al.  Multiplex serological assay for establishing serological profiles of polymorphic, closely related peptide antigens , 2021, MethodsX.

[5]  Pengfei Wang.  Natural and Synthetic Saponins as Vaccine Adjuvants , 2021, Vaccines.

[6]  M. Travassos,et al.  Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. , 2021, Vaccine.

[7]  D. Wirth,et al.  Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine. , 2021, Vaccine.

[8]  Dianne J Terlouw,et al.  Cost-effectiveness and public health impact of RTS,S/AS01 E malaria vaccine in Malawi, using a Markov static model , 2020, Wellcome open research.

[9]  Linda A. Murray,et al.  A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults , 2020, The Journal of infectious diseases.

[10]  Z. Beck,et al.  Army Liposome Formulation (ALF) family of vaccine adjuvants , 2020, Expert review of vaccines.

[11]  Z. Beck,et al.  Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin , 2019, Malaria Journal.

[12]  C. Sauboin,et al.  Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries , 2019, MDM policy & practice.

[13]  N. Waters,et al.  Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). , 2019, Vaccine.

[14]  S. Chaudhury,et al.  Identification of Immune Signatures of Novel Adjuvant Formulations Using Machine Learning , 2018, Scientific Reports.

[15]  Kwaku Poku Asante,et al.  Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children , 2018, BMC Medicine.

[16]  R. A. van den Berg,et al.  Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity , 2017 .

[17]  A. Wallqvist,et al.  Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis , 2017, Scientific Reports.

[18]  N. Waters,et al.  Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. , 2017, Vaccine.

[19]  A. Hill,et al.  Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine , 2017, Scientific Reports.

[20]  Anthony D. May,et al.  Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes , 2017, Malaria Journal.

[21]  N. Waters,et al.  Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. , 2016, The Journal of infectious diseases.

[22]  Juliana K. Wambua,et al.  Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. , 2016, The New England journal of medicine.

[23]  Jason A. Regules,et al.  Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine , 2016, Scientific Reports.

[24]  A. Wallqvist,et al.  The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity , 2016, Malaria Journal.

[25]  Z. Beck,et al.  Liposomal adjuvants for human vaccines , 2016, Expert opinion on drug delivery.

[26]  Trevor Bedford,et al.  Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. , 2015, The New England journal of medicine.

[27]  Michael D. Porter,et al.  Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses , 2015, PloS one.

[28]  Z. Beck,et al.  Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. , 2015, Vaccine.

[29]  Shinn-Jang Hwang,et al.  Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.

[30]  Z. Beck,et al.  Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. , 2015, Biochimica et biophysica acta.

[31]  Michael D. Porter,et al.  IgG2 Antibodies against a Clinical Grade Plasmodium falciparum CSP Vaccine Antigen Associate with Protection against Transgenic Sporozoite Challenge in Mice , 2014, PloS one.

[32]  Joe D. Cohen,et al.  Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines , 2014, Human vaccines & immunotherapeutics.

[33]  T. Richie,et al.  Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum , 2013, Malaria Journal.

[34]  S. Meshnick,et al.  Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, Malawi , 2013, Scientific Reports.

[35]  D. Carucci,et al.  DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.

[36]  Michael B. Doud,et al.  Unexpected fold in the circumsporozoite protein target of malaria vaccines , 2012, Proceedings of the National Academy of Sciences.

[37]  C. Ockenhouse,et al.  The RTS,S vaccine candidate for malaria , 2011, Expert review of vaccines.

[38]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[39]  P. Sinnis,et al.  The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion , 2005, The Journal of experimental medicine.

[40]  M. Moser,et al.  The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. , 2000, International immunology.

[41]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[42]  J. Sadoff,et al.  Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. , 1995, The Journal of infectious diseases.

[43]  S. Hoffman,et al.  SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE , 1987, The Lancet.

[44]  R. Schwarz,et al.  Strain variation in the circumsporozoite protein gene of Plasmodium falciparum. , 1987, Molecular and biochemical parasitology.

[45]  V. Nussenzweig,et al.  Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes , 1983, The Journal of experimental medicine.

[46]  V. Nussenzweig,et al.  Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax , 1982, The Journal of experimental medicine.